Catalyst Pharmaceuticals, Inc. (CPRX)
CPRX Stock Price Chart
Explore Catalyst Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CPRX price movements and trends.
CPRX Company Profile
Discover essential business fundamentals and corporate details for Catalyst Pharmaceuticals, Inc. (CPRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2006
Employees
181.00
Website
https://www.catalystpharma.comCEO
Richard John Daly
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
CPRX Financial Timeline
Browse a chronological timeline of Catalyst Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.52, while revenue estimate is $136.77M.
Earnings released on 6 Aug 2025
EPS came in at $0.68 surpassing the estimated $0.58 by +17.24%, while revenue for the quarter reached $146.56M , beating expectations by +4.36%.
Earnings released on 7 May 2025
EPS came in at $0.68 surpassing the estimated $0.53 by +28.30%, while revenue for the quarter reached $141.42M , beating expectations by +7.85%.
Earnings released on 26 Feb 2025
EPS came in at $0.70 surpassing the estimated $0.32 by +118.75%, while revenue for the quarter reached $141.82M , beating expectations by +5.68%.
Earnings released on 6 Nov 2024
EPS came in at $0.57 surpassing the estimated $0.49 by +16.33%, while revenue for the quarter reached $128.70M , missing expectations by -4.05%.
Earnings released on 7 Aug 2024
EPS came in at $0.56 surpassing the estimated $0.42 by +33.33%, while revenue for the quarter reached $122.71M , beating expectations by +9.69%.
Earnings released on 8 May 2024
EPS came in at $0.38 surpassing the estimated $0.34 by +11.76%, while revenue for the quarter reached $98.51M , missing expectations by -12.01%.
Earnings released on 28 Feb 2024
EPS came in at $0.53 surpassing the estimated $0.48 by +10.42%, while revenue for the quarter reached $110.57M , meeting expectations.
Earnings released on 8 Nov 2023
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $102.69M , missing expectations by -2.90%.
Earnings released on 9 Aug 2023
EPS came in at $0.33 surpassing the estimated $0.25 by +32.00%, while revenue for the quarter reached $99.58M , beating expectations by +1.98%.
Earnings released on 10 May 2023
EPS came in at $0.26 falling short of the estimated $0.32 by -18.75%, while revenue for the quarter reached $85.37M , missing expectations by -7.94%.
Earnings released on 15 Mar 2023
EPS came in at $0.22 surpassing the estimated $0.21 by +4.76%, while revenue for the quarter reached $60.76M , beating expectations by +4.59%.
Earnings released on 9 Nov 2022
EPS came in at $0.20 surpassing the estimated $0.19 by +5.26%, while revenue for the quarter reached $57.24M , beating expectations by +6.61%.
Earnings released on 9 Aug 2022
EPS came in at $0.20 surpassing the estimated $0.17 by +17.65%, while revenue for the quarter reached $53.11M , beating expectations by +7.92%.
Earnings released on 10 May 2022
EPS came in at $0.12 falling short of the estimated $0.14 by -14.29%, while revenue for the quarter reached $43.09M , beating expectations by +0.78%.
Earnings released on 16 Mar 2022
EPS came in at $0.09 falling short of the estimated $0.12 by -25.00%, while revenue for the quarter reached $38.31M , beating expectations by +0.33%.
Earnings released on 9 Nov 2021
EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $35.95M , beating expectations by +3.94%.
Earnings released on 9 Aug 2021
EPS came in at $0.16 surpassing the estimated $0.09 by +77.78%, while revenue for the quarter reached $36.37M , beating expectations by +7.74%.
Earnings released on 10 May 2021
EPS came in at $0.11 surpassing the estimated $0.09 by +22.22%, while revenue for the quarter reached $30.21M , missing expectations by -18.18%.
Earnings released on 15 Mar 2021
EPS came in at $0.11 surpassing the estimated $0.09 by +22.22%, while revenue for the quarter reached $31.01M .
Earnings released on 9 Nov 2020
EPS came in at $0.11 surpassing the estimated $0.09 by +22.22%, while revenue for the quarter reached $29.32M .
CPRX Stock Performance
Access detailed CPRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.